EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis, and anti-cancer evaluation of the novel conjugate of gemcitabine's ProTide prodrug based on CD13

Liang Zhang, Geng Jia, Zhongqiang Li, Simin Sun, Yuxin Chen, Jianchun Zhao, Xuejian Wang, Wenfang Xu, Fanbo Jing, Yuqi Jiang, Xiaoyang Li

Bioorganic Chemistry · 2025

DOI: 10.1016/j.bioorg.2025.108293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Liang Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266…. Hauptthemen laut MEDLINE: Prodrugs, Gemcitabine, Deoxycytidine, Drug Design. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China, Fundamental Research Funds for the Central Universities, Shandong Province Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NUC1031 is a gemcitabine ProTide prodrug which is currently undergoing phase III. CD13 inhibitor bestatin is utilized as an adjunct therapy in conjunction with chemotherapy for cancer treatment, which has limitations in cytotoxic efficacy. In this study, we designed and synthesized a novel series of bestatin-gemcitabine's ProTide prodrug conjugates aimed at enhancing the antitumor efficacy of NUC1031. The representative compound 5f demonstrates a 10-fold increase in anti-proliferative activity compared to NUC-1031, with an IC50 of 8.5 nM against the prostate cancer cell line 22Rv1. In vitro and in vivo pharmacokinetic studies revealed that compound 5f gradually degrades into the metabolic product 17, potentially extending its anti-tumor activity. 5f demonstrates significant in vivo anti-tumor activity in 22Rv1 xenograft tumor models. Our findings indicate that 5f shows strong potential for further development as a candidate for the treatment of prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsGemcitabineDeoxycytidineDrug DesignCell ProliferationAntineoplastic AgentsDrug Screening Assays, AntitumorCD13 AntigensDose-Response Relationship, DrugHumansAnimalsStructure-Activity RelationshipMolecular StructureMiceMaleCell Line, TumorMice, NudeNeoplasms, ExperimentalProstatic NeoplasmsProTides

Stichwörter der Autor:innen

Anti-prostate cancerBestatinCD13 inhibitorGemcitabine ProTide prodrug

Substanzen

ProdrugsGemcitabineDeoxycytidineAntineoplastic AgentsCD13 AntigensProTides

Autor:innen und Institutionen

  • Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China.
  • Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China.; Marine Biomedical Research Institute of Qingdao, Qingdao,…
  • School of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong, PR China.
  • Marine Biomedical Research Institute of Qingdao, Qingdao, Shandong, 266071, PR China.
  • Department of Pharmacy, The Affiliated Hospital of Qingdao University, Shandong, Qingdao, China.. Electronic address: jingbf178@sina.com.

Förderung

  • Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China
  • Fundamental Research Funds for the Central Universities
  • Shandong Province Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, L., Jia, G., Li, Z., Sun, S., Chen, Y., Zhao, J., Wang, X., Xu, W., Jing, F., Jiang, Y., & Li, X. (2025). Design, synthesis, and anti-cancer evaluation of the novel conjugate of gemcitabine's ProTide prodrug based on CD13. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.108293

Vancouver

Zhang L, Jia G, Li Z, Sun S, Chen Y, Zhao J, et al. Design, synthesis, and anti-cancer evaluation of the novel conjugate of gemcitabine's ProTide prodrug based on CD13. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.108293

BibTeX
@article{Zhang2025,
  author = {Zhang, Liang and Jia, Geng and Li, Zhongqiang and Sun, Simin and Chen, Yuxin and Zhao, Jianchun and Wang, Xuejian and Xu, Wenfang and Jing, Fanbo and Jiang, Yuqi and Li, Xiaoyang},
  title = {Design, synthesis, and anti-cancer evaluation of the novel conjugate of gemcitabine's ProTide prodrug based on CD13},
  journal = {Bioorganic Chemistry},
  year = {2025},
  doi = {10.1016/j.bioorg.2025.108293}
}
Kostenlos starten →